Autologous stem cell transplantation for patients aged 60 years or older with refractory or relapsed classical Hodgkin's lymphoma: a retrospective analysis from the French Society of Bone Marrow Transplantation and Cell Therapies (SFGM-TC).
Fiche publication
Date publication
juillet 2016
Journal
Bone marrow transplantation
Auteurs
Membres identifiés du Cancéropôle Est :
Dr CHRETIEN Marie-Lorraine
Tous les auteurs :
Stamatoullas A, Brice P, Gueye MS, Mareschal S, Chevallier P, Bouabdallah R, Nguyenquoc S, Francois S, Turlure P, Ceballos P, Monjanel H, Bourhis JH, Guillerm G, Mohty M, Biron P, Cornillon J, Belhadj K, Bonmati C, Dilhuydy MS, Huynh A, Bernard M, Chrétien ML, Peffault de Latour R, Tilly H
Lien Pubmed
Résumé
This report retrospectively analyzed the outcome of 91 patients aged 60 years or older with refractory/relapsed (R/R) classical Hodgkin's lymphoma (cHL) who underwent autologous stem cell transplantation (ASCT) between 1992 and 2013 and were reported to the French Society of Bone Marrow Transplantation and Cell Therapies registry. The median age at transplant was 63 years. The majority of patients exhibited disease chemosensitivity to salvage treatment (57 complete responses, 30 partial responses, 1 progressive disease and 3 unknown). The most frequent conditioning regimen consisted of BCNU, cytarabine, etoposide, melphalan (BEAM) chemotherapy (93%). With a median follow-up of 54 months, 5-year estimates of overall survival (OS) and progression free survival (PFS) for the entire group were 67 and 54%, respectively. Despite the missing data, in univariate analysis, the number of salvage chemotherapy lines (1-2 versus ⩾3) significantly influenced the OS, unlike the other prognostic factors (stage III-IV at relapse, disease status before ASCT and negative positron emission tomography (PET) scan) encountered in younger patients. In spite of its limitations, this retrospective study with a long-term follow-up suggests that ASCT is a valid treatment option for chemosensitive R/R cHL in selected elderly patients, with an acceptable rate of toxicity.
Mots clés
Age Factors, Aged, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Female, Follow-Up Studies, Hematopoietic Stem Cell Transplantation, adverse effects, Hodgkin Disease, mortality, Humans, Male, Middle Aged, Retrospective Studies, Salvage Therapy, methods, Survival Analysis, Transplantation, Autologous
Référence
Bone Marrow Transplant.. 2016 Jul;51(7):928-32